Intestinal lipid absorption and transport in type 2 diabetes
| العنوان: | Intestinal lipid absorption and transport in type 2 diabetes |
|---|---|
| المؤلفون: | Bruno, Vergès |
| المصدر: | Diabetologia. 65:1587-1600 |
| بيانات النشر: | Springer Science and Business Media LLC, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Dipeptidyl-Peptidase IV Inhibitors, Pioglitazone, Lipoproteins, Endocrinology, Diabetes and Metabolism, Chylomicron Remnants, Sodium, Hyperlipidemias, Lipid Metabolism, Postprandial Period, Metformin, Lipoprotein Lipase, Cholesterol, Glucose, Diabetes Mellitus, Type 2, Intestinal Absorption, Glucagon-Like Peptide 1, Chylomicrons, Internal Medicine, Humans, Insulin, Glycoside Hydrolase Inhibitors, Apolipoprotein B-48, Triglycerides |
| الوصف: | Postprandial hyperlipidaemia is an important feature of diabetic dyslipidaemia and plays an important role in the development of cardiovascular disease in individuals with type 2 diabetes. Postprandial hyperlipidaemia in type 2 diabetes is secondary to increased chylomicron production by the enterocytes and delayed catabolism of chylomicrons and chylomicron remnants. Insulin and some intestinal hormones (e.g. glucagon-like peptide-1 [GLP-1]) influence intestinal lipid metabolism. In individuals with type 2 diabetes, insulin resistance and possibly reduced GLP-1 secretion are involved in the pathophysiology of postprandial hyperlipidaemia. Several factors are involved in the overproduction of chylomicrons: (1) increased expression of microsomal triglyceride transfer protein, which is a key enzyme in chylomicron synthesis; (2) higher stability and availability of apolipoprotein B-48; and (3) increased de novo lipogenesis. Individuals with type 2 diabetes present with disorders of cholesterol metabolism in the enterocytes with reduced absorption and increased synthesis. The increased production of chylomicrons in type 2 diabetes is also associated with a reduction in their catabolism, mostly because of a reduction in activity of lipoprotein lipase. Modification of the microbiota, which is observed in type 2 diabetes, may also generate disorders of intestinal lipid metabolism, but human data remain limited. Some glucose-lowering treatments significantly influence intestinal lipid absorption and transport. Postprandial hyperlipidaemia is reduced by metformin, pioglitazone, alpha-glucosidase inhibitors, dipeptidyl peptidase 4 inhibitors and GLP-1 agonists. The most pronounced effect is observed with GLP-1 agonists, which reduce chylomicron production significantly in individuals with type 2 diabetes and have a direct effect on the intestine by reducing the expression of genes involved in intestinal lipoprotein metabolism. The effect of sodium-glucose cotransporter 2 inhibitors on intestinal lipid metabolism needs to be clarified. |
| تدمد: | 1432-0428 0012-186X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e671ef8b0a5a063ea7453a76796027aeTest https://doi.org/10.1007/s00125-022-05765-8Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....e671ef8b0a5a063ea7453a76796027ae |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14320428 0012186X |
|---|